Tag: INSIGHT-004 Phase I trial
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
APS Industrial expands regional footprint with Control Technologies acquisition
APS Industrial (APS) is expanding its regional presence through the acquisition of Albury-based Control Technologies, a move the industrial products supplier said will strengthen its local service capability and support further investment in warehousing, stockholding and technical support.
